Xiaokuang Lai InspectorProfile

This FDA InspectorProfile is a report of relevant audit-related information on Xiaokuang Lai, a U.S. Food & Drug Administration investigator who primarily conducts inspections in the area of Human Drugs.

Product Description

This InspectorProfile report is updated through Feb 2020 and lists Xiaokuang Lai's inspections in 17 countries: Japan, United States, Serbia, Italy, Finland, Germany, India, Singapore, Ireland, Belgium, Taiwan, Switzerland, Romania, Austria, China, France, and United Kingdom.

FDA audits are stressful. Whether you are issued a 483 depends largely on your compliance with GxP and predicate rules; but it can also depend on the Agency's current focus and the tendencies of your specific investigator(s). FDAzilla has curated Xiaokuang Lai's inspection information so that you can mitigate investigator-related risks.

Example Report

Below is an example of what a FDAzilla InspectorProfile report contains; This is not the actual data for Xiaokuang Lai.

Product details

• Xiaokuang Lai's metrics:
  • 483 issue rate, total inspections, total 483s
  • Most common citations (based on CFR), CFR description, and citation frequency
  • Total inspections, total 483s
  • Longest / shortest inspection in duration - all time, last year
  • Total warning letters
• Inspection details for each inspection (since 2000) Xiaokuang Lai has conducted including:
  • Company, site inspected, duration of inspection
  • Co-inspectors Frederick Razzaghi, Arie Menachem, Christopher Leach, Anita Narula, Francis Guidry, year of last co-inspection, number of co-inspections
  • If a 483 issued, and whether or not it resulted in a warning letter.

Note: The EIR and 483 documents are sold separately.